Aligos Therapeutics Inc (ALGS)
1.11
-0.02
(-1.77%)
USD |
NASDAQ |
Mar 24, 16:00
1.11
0.00 (0.00%)
After-Hours: 20:00
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 47.66M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -59.50% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 3.408 |
| Price to Book Value | 0.4587 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.00 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | -- |
News
Headline
Wire
Time (ET)
SA Breaking News
03/09 16:46
MT Newswires
03/09 16:16
Yahoo
03/09 16:05
Globe Newswire
03/09 16:05
Globe Newswire
02/16 08:00
Globe Newswire
02/14 08:00
MT Newswires
02/09 13:49
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 05/04/2023* | -- | Results | Q1 2023 | -- | -- | -- | |
| 03/09/2023 | -- | Results | Q4 2022 | -0.51 | -0.51 | -0.66% | |
| 11/02/2022 | -- | Results | Q3 2022 | -0.44 | -0.58 | 24.25% | |
| 08/04/2022 | -- | Results | Q2 2022 | -0.47 | -0.67 | 29.63% | |
| 05/04/2022 | -- | Results | Q1 2022 | -0.84 | -0.78 | -7.69% | |
| 03/10/2022 | -- | Results | Q4 2021 | -0.89 | -0.83 | -6.78% | |
| 11/04/2021 | -- | Results | Q3 2021 | -0.78 | -0.82 | 5.28% | |
| 08/05/2021 | -- | Results | Q2 2021 | -0.79 | -0.81 | 2.67% |
*Estimated Date/Time
Earnings
Profile
Edit
| Aligos Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others. |
| URL | https://www.aligos.com |
| Investor Relations URL | https://investor.aligos.com/ |
| HQ State/Province | California |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | N/A |
| Next Earnings Release | May. 04, 2023 (est.) |
| Last Earnings Release | Mar. 09, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | -- |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.00 |
| Yield to Sector | 0.00 |
| Yield to Industry | 0.00 |
| Last Dividend Amt. | -- |
| Dividend Frequency | -- |
| Last Ex-Dividend Date | -- |
| Yield (TTM) | 0% |
| Forward Yield | -- |
| Payout Ratio | 0.00% |
| Cash Payout Ratio | 0.00% |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk
Total Returns Comparison
Annual Total Returns Versus Peers
As of March 23, 2023.
Fundamentals
| Revenue (TTM) | 13.91M |
| Total Expenses (TTM) | 111.49M |
| Net Income (TTM) | -96.05M |
| Total Assets (Quarterly) | 146.69M |
| Total Liabilities (Quarterly) | 42.79M |
| Shareholders Equity (Quarterly) | 103.90M |
| Cash from Operations (TTM) | -79.39M |
| Cash from Investing (TTM) | -26.29M |
| Cash from Financing (TTM) | 0.164M |
Ratings
Profile
Edit
| Aligos Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others. |
| URL | https://www.aligos.com |
| Investor Relations URL | https://investor.aligos.com/ |
| HQ State/Province | California |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | N/A |
| Next Earnings Release | May. 04, 2023 (est.) |
| Last Earnings Release | Mar. 09, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Nasdaq | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| ALGS Tweets |